World journal of experimental medicine最新文献

{"title":"PI3K/AKT/GSK3β regulatory axis in bone mesenchymal stem cells initiates diabetic myocardial infarction <i>via</i> miR-142-3p.","authors":"Ning Gao, Peng-Fei Wu, Ming-Wen Wu, Yu-Meng Li, Xu Liang, Fei-Fei Wang, Xue-Jing Li, Qing-Qing Shen, Tian-Peng Zheng, Xiao-Ling Liu, Yi Sun, Liu-Xue Yang","doi":"10.5493/wjem.v15.i3.103948","DOIUrl":"10.5493/wjem.v15.i3.103948","url":null,"abstract":"<p><strong>Background: </strong>We aimed to identify the key proteins of miR-142-3p that regulate ferroptosis and ultimately control the downstream effectors of cardiomyocyte growth.</p><p><strong>Aim: </strong>To investigate the role of miR-142-3p in regulating ferroptosis and its impact on diabetes-induced myocardial infarction <i>via</i> the PI3K/AKT/GSK3β pathway.</p><p><strong>Methods: </strong>We constructed bones mesenchymal stem cells (BMCs) with low miR-142-3p expression and investigated its role using cell flow cytometry and western blotting (WB). A diabetes myocardial infarction model was established using streptozotocin and coronary artery ligation. The rats were divided into six groups (<i>n</i> = 15 per group): Control, sham surgery model, liraglutide intervention, BMCs intervention, and low miR-142-3p BMCs intervention. Interventions lasted for 7 days and BMCs injected for once. Blood glucose levels were monitored, and myocardial infarction improvements were assessed <i>via</i> electrocardiogra, general heart observation, staining techniques, and WB analysis.</p><p><strong>Results: </strong>We observed that miR-142-3p increased BMC apoptosis and affected AKT and GSK3β. The myocardial infarction drug, liraglutide, BMCs, and miR-142-3p low expression BMCs intervention showed improvement in differing degrees. The liraglutide and BMCs showed significant blood glucose reduction (0.05). BMCs increased the expression of PI3K, AKT, and GSK3, leading to an increase in the myocardial infarction intervention group, liraglutide, and BMCs intervention groups. The low miR-142-3p expression intervention with BMCs group had the lowest PI3K and AKT protein expression. Liraglutide improved ferroptosis markers (increased COX-2, decreased GPX4 and CHCHD6). Low miR-142-3p BMCs increased COX-2, GPX4, and CHCHD6. CCM3 and VEGFR2 expression increased in BMCs and low miR-142-3p groups, promoting myocardial repair, but decreased in the low miR-142-3p groups.</p><p><strong>Conclusion: </strong>The preliminary results showed that the therapeutic mechanism of BMCs in diabetes myocardial infarction may involve miR-142-3p <i>via</i> the PI3K/AKT/GSK-3β axis, which jointly inhibits ferroptosis and programmed death.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"103948"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship of diabetes mellitus with prognostic factors in breast cancer.","authors":"Songul Peltek Ozer, Fatih Keyif, Ferdi Bolat, Bahri Ozer, Gulali Aktas","doi":"10.5493/wjem.v15.i3.108318","DOIUrl":"10.5493/wjem.v15.i3.108318","url":null,"abstract":"<p><strong>Background: </strong>Hyperglycemia secondary to diabetes can lead to organ failure unless properly controlled, and it is associated with numerous health issues, particularly metabolic problems. Breast cancer is one of the most common malignancies in females worldwide and represents a major health concern due to its morbidity and mortality. The progression of the disease and the response to treatment depend on numerous variables, including both tumor biology and patient-related factors. Key prognostic indicators include age, tumor size, lymph node involvement, histological type, hormone receptor status, and expression of biomarkers such as <i>HER2</i>.</p><p><strong>Aim: </strong>To investigate the relationship between preoperative blood glucose levels and cancer prognostic factors in patients diagnosed with breast cancer.</p><p><strong>Methods: </strong>In this study patients diagnosed with breast cancer were classified into two groups: Those with blood glucose levels < 125 mg/dL and those with levels > 125 mg/dL. Estrogen and progesterone receptor positivity, Ki-67 percentage, Cerb2 positivity, number of positive lymph nodes, and presence of lymphovascular invasion were examined histopathologically.</p><p><strong>Results: </strong>The study included 246 patients with breast cancer: 196 were in the normal glucose group and 50 were in the elevated glucose group. In the normal glucose group, 68% of the tumors were left-sided and 32% were right-sided, while all tumors in the elevated glucose group were left-sided. This difference was statistically significant (<i>P</i> < 0.001). Tumor size, Ki-67, and the number of positive lymph nodes were not associated with blood glucose in patients with breast cancer (<i>P</i> > 0.05 for all). However, blood glucose was correlated with age in this population. Correlation analyses revealed that blood glucose was positively correlated with age (<i>r</i> = 0.23, <i>P</i> < 0.001). Additionally, Ki-67 was correlated with tumor size (<i>r</i> = 0.14, <i>P</i> = 0.03) and age (<i>r</i> = -0.18, <i>P</i> = 0.005).</p><p><strong>Conclusion: </strong>Our study highlighted the complex interplay between metabolic factors, such as fasting glucose levels, and breast cancer characteristics. Elevated glucose levels were associated with older age. The significant association between tumor laterality and glucose levels underscores the need for further investigation into the collective influence of metabolic and anatomical factors on breast cancer development and progression.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"108318"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ophthalmological manifestations in autoimmune diseases: Overcoming diagnostic and therapeutic challenges.","authors":"Issa El Kaouri, Ioannis Deligiannis, Konstantina Bakopoulou, Paraskevas Panagiotis Sdralis, Viara Shoumnalieva-Ivanova, Russka Shumnalieva, Tsvetelina Velikova","doi":"10.5493/wjem.v15.i3.104431","DOIUrl":"10.5493/wjem.v15.i3.104431","url":null,"abstract":"<p><p>Autoimmune diseases frequently present with ophthalmological manifestations, posing significant diagnostic and therapeutic challenges. This review delved into the complex interplay between autoimmunity and ocular health, highlighting common manifestations such as uveitis, keratitis, and optic neuritis. We explored advanced diagnostic tools and techniques to improve early detection and accurate diagnosis. Additionally, the review addressed current therapeutic strategies, emphasizing the need for tailored treatments to manage ocular symptoms effectively while minimizing systemic side effects. By overcoming these challenges we aimed to enhance patient outcomes and quality of life for those affected by autoimmune-related eye diseases.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"104431"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of propolis and honey in hyperglycemia-induced kidney and liver injuries, proteinuria, and oxidant and antioxidant parameters.","authors":"Soumaya Touzani, Noori Al-Waili, Hassan Laaroussi, Abderrazak Aboulghazi, Nawal Hamas, Hamada Imtara, Asmae El Ghouizi, Ilham ElArabi, Ahmed Al-Waili, Badiaa Lyoussi","doi":"10.5493/wjem.v15.i3.99330","DOIUrl":"10.5493/wjem.v15.i3.99330","url":null,"abstract":"<p><strong>Background: </strong>Propolis and honey are known for their antioxidant, hypoglycemic, and antiproteinuric effects.</p><p><strong>Aim: </strong>To explore the effect of propolis, and honey, against D-glucose-induced hyperglycemia, acute kidney injury (AKI), liver injury, dyslipidemia, and changes in the oxidants and antioxidants in renal, hepatic, and pancreatic tissues.</p><p><strong>Methods: </strong>The chemical analysis and antioxidant content of propolis and honey and their effect on alpha-amylase and alpha-glucosidase activity were studied. The study included five groups of male rats; four groups (2, 3, 4 and 5) were treated with D-glucose, and one group was untreated, group 1. In addition to D-glucose, groups 3, 4, and 5 were treated with propolis, honey, and their combination, respectively. Blood glucose levels, liver and renal function tests, urine protein and electrolytes, oxidant and antioxidant parameters, and histopathological changes in hepatic, renal, and pancreatic tissues were examined.</p><p><strong>Results: </strong>Propolis contains a higher level of total protein and exhibits a higher antioxidant activity. Honey has a higher alpha-amylase and glucosidase inhibitory activity than propolis. D-glucose caused a significant elevation of blood glucose, insulin, homeostasis model assessment, blood urea, creatinine, lipid parameters, liver enzymes, and urine protein levels. It significantly increases malondialdehyde and decreases antioxidant parameters in pancreatic, hepatic, and renal tissues. D-glucose caused histopathological changes in hepatic, renal, and pancreatic tissues; these changes were significantly ameliorated by honey and propolis.</p><p><strong>Conclusion: </strong>Propolis, honey, or their combination treated hyperglycemia, AKI, proteinuria, liver injury, and dyslipidemia induced by D-glucose, most likely, through their antioxidant activity and alpha-amylase and alpha-glucosidase inhibitory activity. This will pave the way for testing this natural combination in the prevention of diabetic complications, as a complement to basic therapies.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"99330"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of differential plasma proteins levels in the diagnosis of epithelial ovarian cancer.","authors":"Noha H Ibrahim, Mona S Abdellateif, Dina S Serag, Ahmed Laymouna, Mennatallah S Elaguizy, Radwa Marawan Abdel Halim","doi":"10.5493/wjem.v15.i3.107711","DOIUrl":"10.5493/wjem.v15.i3.107711","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OC) is the most lethal gynecological cancer among females, and its early diagnosis could help for better outcomes of the patients.</p><p><strong>Aim: </strong>To investigate the utility of serum insulin-like growth factors-binding proteins 2 (IGFBP2), secreted phosphoprotein 1 (SPP1), thrombospondin 1 protein (TSP1) and D-dimer levels in addition to currently used biomarkers [cancer antigen 125 (CA125) and human epididymis protein 4 (HE4)] in the diagnosis of epithelial OC (EOC).</p><p><strong>Methods: </strong>This is a case-control study that included fifty females diagnosed with EOC, 10 females with benign ovarian masses recruited from the Egyptian National Cancer Institute, and 30 healthy females as a control group. All subjects were assessed for serum HE4, CA125, IGFBP2, TSP1 and SPP1 measurement by enzyme-linkedimmunosorbent assay.</p><p><strong>Results: </strong>There was a statistically significant difference in serum levels between EOC, benign ovarian masses, and healthy control groups regarding CA125 and SPP1 (<i>P</i> < 0.001 for both markers), while HE4 and IGFBP2 increased significantly in EOC compared to healthy control groups (<i>P</i> < 0.001 for all markers) with no significant difference between EOC and benign ovarian masses groups. However, there was no statistically significant difference among EOC, benign ovarian masses, and healthy control groups regarding the TSP1 serum levels (<i>P</i> = 0.051). Receiver operating characteristic analysis revealed that combined assessment of SPP1 with CA125 or TSP1 increased the diagnosis of EOC patients to a sensitivity, specificity, and area under curve of (93.3%, 100%, 0.968; respectively, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>SPP1 may be a potential marker for the differentiation between benign and malignant ovarian masses, while IGFBP2 can differentiate between healthy females and females with ovarian masses. Combining SPP1 with CA125 or TSP1 provides high sensitivity and specificity for the detection of EOC patients<b>.</b></p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"107711"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gas chromatography-mass spectrometry-based plasma metabolomics analysis in hypertensive patients with Yin deficiency and Yang hyperactivity syndrome.","authors":"Dinala Jialiken, Jing Dai, Ya-Dong Fan, Hai-Tao Zhang, Jin-Jun Shan, Wei-Chen Xu, Chong Zou","doi":"10.5493/wjem.v15.i3.103154","DOIUrl":"10.5493/wjem.v15.i3.103154","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Hypertension is a significant global health concern and serves as a critical risk factor for cardiovascular diseases, stroke, and renal failure. Traditional Chinese Medicine (TCM) has been utilized for an extended period to address hypertension, with the syndrome known as Yin deficiency and Yang hyperactivity syndrome (YDYHS) frequently observed in individuals with elevated blood pressure. This syndrome is characterized by symptoms including dizziness, tinnitus, irritability, and insomnia, which are thought to result from an imbalance between Yin, representing the cooling and nourishing aspects, and Yang, denoting the active and warming aspects of the body. Despite the prevalent application of TCM in clinical settings, the metabolic mechanisms underlying the YDYHS in the context of hypertension remain inadequately elucidated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To explore the differential plasma metabolites and associated pathways in hypertensive patients with YDYHS using gas chromatography-mass spectrometry (GC-MS) to elucidate the distinctive blood metabolite pattern in this patient population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;GC-MS was used to analyze plasma samples from 51 hypertensive patients with YDYHS and 20 healthy controls. Chemometric methods, including principal component analysis and partial least squares discriminant analysis, were employed to identify potential biochemical patterns. Simultaneously, the high-quality Kyoto Encyclopedia of Genes and Genomes metabolic pathways database was used to identify associated metabolic pathways. Using variable importance in projection and receiver operating characteristic curve analyses, potential biomarkers were extracted to assess their clinical utility.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Metabolomic profiling of hypertensive patients with YDYHS identified 20 potential biomarkers (4-hydroxybenzoic acid, pectin, 1,2,3-trihydroxybenzene, D-ribose, 3-hydroxybutyric acid, quinic acid, L-lysine, oleic acid, 2-hydroxybutyric acid, linoleic acid, citric acid, alpha-tocopherol, D-glucuronic acid, glycerol, N-acetyl-L-aspartic acid, beta-mannosylglycerate, indolelactic acid, L-glutamic acid, D-maltose, L-aspartic acid) and four metabolic pathways (linoleic acid metabolism; alanine, aspartate and glutamate metabolism; D-glutamine and D-glutamate metabolism; arginine biosynthesis). The identified differential metabolites may serve as potential biomarkers for distinguishing hypertensive patients with YDYHS from healthy controls. The area under the curve values ranged from 0.750 to 0.866. Receiver operating characteristic curve analysis showed that these differential metabolites can effectively classify hypertensive patients with YDYHS and healthy individuals.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The metabolomic analysis revealed a distinct blood metabolite pattern in hypertensive patients with YDYHS compared to the healthy control group, highlighting the potential role of the identified","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"103154"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental gallbladder mucocele mimicking acute cholecystitis: A case report and review of literature.","authors":"Aran Thiravialingam, Karthik Sriganeshan, Hisham F Bahmad, Francesca Polit, Asma Ahmed, Devendra Joshi, Robert Poppiti","doi":"10.5493/wjem.v15.i3.107248","DOIUrl":"10.5493/wjem.v15.i3.107248","url":null,"abstract":"<p><strong>Background: </strong>Gallbladder mucocele, also known as gallbladder hydrops, is a rare condition characterized by the distention of the gallbladder due to the accumulation of fluid or mucus within its lumen, primarily attributed to obstruction arising from a gallstone in the cystic duct or gallbladder neck.</p><p><strong>Case summary: </strong>We present a case of a 67-year-old woman with an incidentally discovered gallbladder mucocele, shedding light on the clinical presentation, causes, and histopathological findings. We performed a literature review including an analysis of 27 case reports, revealing the diverse spectrum of causative factors, clinical manifestations, diagnosis, and management.</p><p><strong>Conclusion: </strong>This study underscores the importance of considering alternative diagnoses and highlights the significance of imaging techniques in narrowing down the differential diagnosis and histopathologic examination for a definitive diagnosis.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"107248"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases.","authors":"Elie Chamchoum, Nadia Katrib, Nicolas Nassif, Yara Ratel, Mohamad Ali Rida","doi":"10.5493/wjem.v15.i3.107020","DOIUrl":"10.5493/wjem.v15.i3.107020","url":null,"abstract":"<p><p>Glucagon-like peptide-1 (GLP-1) and its receptor agonists (GLP-1RAs) are well-established therapies for metabolic conditions such as type 2 diabetes and obesity due to their ability to enhance insulin secretion, promote weight loss, and regulate blood glucose levels. Emerging evidence, however, indicates that GLP-1RAs may also have therapeutic potential in inflammatory and autoimmune conditions. This review explores the evolving role of GLP-1RAs in managing rheumatic diseases, including osteoarthritis, rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Studies suggest that GLP-1RAs reduce inflammation by modulating immune cell activity, increasing anti-inflammatory cytokine production, shifting macrophage polarization toward an anti-inflammatory phenotype, and enhancing regulatory T-cell function to maintain immune homeostasis. These immunomodulatory effects point toward a promising adjunctive strategy in current clinical practice for patients with rheumatic diseases, particularly those with metabolic comorbidities. Further clinical trials are warranted to validate these findings, clarify underlying mechanisms, and assess long-term safety, ultimately paving the way for novel treatment approaches in rheumatology.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"107020"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of autologous bone marrow aspirate concentrate injection for idiopathic male infertility: A comparative study.","authors":"Ravi Velamoor Rangarajan, Avinash Gandi Devadas, Dhossaradhan Jayakumar Padmanapan, Naveen Jeyaraman, Swaminathan Ramasubramanian, Arulkumar Nallakumarasamy, Sathish Muthu, Madhan Jeyaraman","doi":"10.5493/wjem.v15.i3.107323","DOIUrl":"10.5493/wjem.v15.i3.107323","url":null,"abstract":"<p><strong>Background: </strong>Although limited clinical evidence exists, such as case reports of azoospermia treatment in humans using bone marrow aspirate concentrate (BMAC) injection, these findings provide a compelling foundation for exploring mesenchymal stem cell therapy in male infertility.</p><p><strong>Aim: </strong>To evaluate the safety and efficacy of autologous BMAC injection into human testis for men with severe oligospermia or azoospermia over the existing standard of care pharmacotherapy and lifestyle modifications.</p><p><strong>Methods: </strong>We included patients diagnosed with male infertility of the age group between 35-45 years in this trial comparing BMAC injection therapy with pharmacotherapy and lifestyle modifications over a 6-month follow-up period. Semen analysis was used to evaluate the efficacy of the interventions analyzed.</p><p><strong>Results: </strong>We enrolled 30 patients in the trial with 10 patients in each arm of the trial. Compared to the baseline, neither the BMAC group (<i>P</i> = 0.139) or pharmacotherapy group (<i>P</i> = 0.056) nor the lifestyle modification group (<i>P</i> = 0.112) demonstrated a statistically significant increase in sperm count at 6 months. However, the BMAC group demonstrated a significant increase in sperm count (mean 19.2 million; <i>P</i> = 0.001) compared to the pharmacotherapy group (mean 3.5 million) and lifestyle modification group (mean 2.2 million) at 6 months. Significant improvement was noted in the motility grade (<i>P</i> < 0.001) only in the BMAC group while no changes were noted in the other groups.</p><p><strong>Conclusion: </strong>This trial highlights the potential of autologous BMAC as a promising therapeutic option for male infertility. Despite the absence of significant changes within individual treatment arms, BMAC therapy demonstrated superior efficacy in improving both sperm count and motility compared to standard pharmacotherapy and lifestyle modifications. These findings underscore the potential role of regenerative medicine in addressing severe oligospermia and azoospermia, warranting further research to solidify its clinical applicability.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"107323"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential of adipose tissue in aesthetic medicine.","authors":"Mahmood S Choudhery, Taqdees Arif, Aleeza Afzal, Ruhma Mahmood","doi":"10.5493/wjem.v15.i3.106641","DOIUrl":"10.5493/wjem.v15.i3.106641","url":null,"abstract":"<p><p>Aesthetic medicine is a branch of medicine dedicated to improve an individual's appearance and overall visual appeal. Conventional aesthetic treatments have limitations, including the risk of complications, allergic reactions, and temporary benefits. Adipose tissue offers a promising alternative to conventional aesthetic treatments. The regenerative properties, accessibility and versatility of adipose tissue make it an attractive option for individuals seeking natural and long-lasting aesthetic results. Adipose tissue is rich source of adipose tissue derived stem cells (ASCs), growth factors and extracellular matrix. It can restore and rejuvenate the damaged and aged tissues. Adipose tissue can be used in different formats such as pure adipose tissue grafts, stromal vascular fraction, nanofat, macrofat, microfat and as a pure population of ASCs. In addition, ASC derived exosomes offer a unique cell-free therapy advantages bioactive molecules like growth factors, cytokines, and microRNAs to stimulate collagen production, improve skin texture, and address pigmentation issues. This review highlights the multifaceted potential of adipose tissue in aesthetic medicine. It discusses its diverse applications, the biological mechanisms involved, and emerging therapeutic approaches. Moreover, this review also highlights the challenges and future direction of using adipose tissue-based therapies for aesthetic treatments.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"15 3","pages":"106641"},"PeriodicalIF":0.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}